Alirocumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Alirocumab: From Hypercholesterolemia to Cholesterol Catabolic Process Disease
One-Sentence Summary
Alirocumab (Praluent®) is a PCSK9 inhibitor monoclonal antibody, globally approved for reducing LDL-cholesterol in patients with hypercholesterolemia and atherosclerotic cardiovascular disease, though not yet marketed in Taiwan. The TxGNN model predicts it may be effective for Cholesterol Catabolic Process Disease (encompassing familial hypercholesterolemia, dysbetalipoproteinemia, and related cholesterol metabolism disorders), with 1 completed Phase 3 clinical trial and 19 supporting publications — a prediction that closely mirrors the drug's established global pharmacology and confirms strong model alignment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia / Atherosclerotic Cardiovascular Disease (global approval; no Taiwan license) |
| Predicted New Indication | Cholesterol Catabolic Process Disease |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L1 |
| Taiwan Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, alirocumab is a fully human monoclonal antibody (IgG1 class) targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). Under normal physiology, circulating PCSK9 binds to LDL receptors on the surface of hepatocytes and directs them to lysosomal degradation, reducing LDL-C clearance capacity. By binding and neutralising PCSK9, alirocumab prevents this receptor degradation and allows LDL receptors to recycle back to the cell surface — increasing hepatic uptake of circulating LDL particles and reducing plasma LDL-C by approximately 50–60%.
Cholesterol catabolic process disease encompasses a spectrum of conditions characterised by impaired cholesterol metabolism and clearance, including familial hypercholesterolemia (both heterozygous and homozygous forms), dysbetalipoproteinemia (type 3 hyperlipoproteinemia), and treatment-related dyslipidemia in conditions such as HIV/ART therapy. Because these conditions share the pathological feature of impaired LDL-C clearance — often driven by reduced functional LDL receptor density — alirocumab's mechanism of restoring receptor availability directly addresses the root defect.
The ODYSSEY clinical programme has generated over 47,000 patient-years of placebo-controlled Phase 3 data confirming alirocumab's cardiovascular outcome benefits. The EPIC-HIV trial (NCT03207945) further extends the evidence base to HIV-infected patients with antiretroviral therapy-induced dyslipidemia, a population with uniquely elevated cardiovascular risk. The biological plausibility of the TxGNN prediction is extremely strong, and the cumulative clinical evidence comfortably meets L1 standards.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03207945 | Phase 3 | Completed | 118 | EPIC-HIV: PCSK9 inhibition in treated HIV patients with elevated cardiovascular risk; assessed LDL-C lowering, vascular inflammation, endothelial function, and non-calcified atherosclerotic plaque burden using noninvasive imaging |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38658193 | 2024 | Phase 3 Trial Analysis | Eur Heart J Cardiovasc Pharmacother | ODYSSEY OUTCOMES: alirocumab significantly reduced recurrent ischaemic cardiovascular events and all-cause mortality across 47,296 patient-years; comprehensive safety profile confirmed as favourable throughout follow-up |
| 39913634 | 2025 | RCT Post-hoc Analysis | Diabetes Care | ODYSSEY OUTCOMES post-hoc: alirocumab simultaneously lowers Lp(a) and LDL-C without increasing new-onset type 2 diabetes risk — important safety reassurance for long-term use |
| 36739653 | 2023 | Systematic Review / Meta-analysis | Kardiologia Polska | PCSK9 inhibitors significantly reduce LDL-C and major adverse cardiovascular events; comprehensive synthesis of biochemical, genomic, and clinical outcome evidence |
| 39679827 | 2025 | State-of-the-art Review | Pharmacotherapy | Current and emerging PCSK9-directed therapies (mAbs, siRNA, oral inhibitors) for ASCVD risk reduction; alirocumab positioned as cornerstone non-statin lipid-lowering therapy |
| 38185721 | 2024 | Review | Signal Transduct Target Ther | Comprehensive PCSK9 review spanning lipid metabolism, liver disease, infectious disease, autoimmune disorders, and cancer; broadening therapeutic applications beyond cardiovascular disease |
| 38277255 | 2024 | Review | Curr Opin Lipidol | Two landmark PCSK9 mAb outcomes trials confirm marked LDL-C reduction and cardiovascular benefit; update on novel PCSK9 inhibition strategies in clinical development |
| 39751968 | 2025 | Review | Curr Atheroscler Rep | Novel pharmacological therapies for homozygous familial hypercholesterolemia (HoFH); PCSK9 inhibitors remain critical agents in a multimodal treatment strategy |
| 36422206 | 2022 | Review | Medicina (Kaunas) | Familial hypercholesterolemia diagnostics and treatment options; PCSK9 inhibitors indicated for patients unable to achieve LDL targets on maximally tolerated statins |
| 37686091 | 2023 | Review | Int J Mol Sci | Current dyslipidemia treatment advances: PCSK9 inhibitors achieve superior LDL-C reduction vs statins alone with confirmed cardiovascular outcomes improvement |
| 29526502 | 2018 | Clinical Trial Analysis | Kidney International | Alirocumab effectively and safely lowers LDL-C in chronic kidney disease patients (eGFR 30–59 mL/min/1.73 m²); population-specific pharmacokinetic and safety data from the ODYSSEY programme |
Taiwan Market Information
Alirocumab is currently not marketed in Taiwan — zero active TFDA licenses exist as of the data cutoff (2026-06-01).
For reference: Alirocumab (Praluent®) holds regulatory approval from the U.S. FDA (2015), European EMA (2015), and multiple other jurisdictions for hypercholesterolemia and cardiovascular risk reduction, but has not received TFDA approval. No Taiwan-specific dosage, indication, or product labelling data is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The TxGNN prediction for "cholesterol catabolic process disease" is fully consistent with alirocumab's established global pharmacology and mechanism of action. The ODYSSEY clinical programme — comprising multiple Phase 3 RCTs with over 47,000 patient-years of observation — provides definitive L1 evidence for LDL-C lowering efficacy and cardiovascular outcome benefit. The barrier to Taiwan market introduction is regulatory, not clinical.
To proceed, the following is needed:
- TFDA New Drug Application (NDA) filing with the complete Phase 3 clinical dossier (ODYSSEY OUTCOMES and supporting trials)
- Taiwan-specific pharmacovigilance plan and post-marketing surveillance protocol
- Formal mechanism of action documentation for TFDA submission (filling current DG002 data gap)
- Safety monitoring framework covering: injection site reactions, neurocognitive adverse event surveillance, and hepatic enzyme monitoring
- Pricing and reimbursement strategy aligned with Taiwan National Health Insurance (NHI) formulary criteria and cost-effectiveness thresholds
- Assessment of patient population size in Taiwan with familial hypercholesterolemia or statin-intolerant high-risk cardiovascular disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.